Clinical trials: Acute Ischemia
Acute Ischemic Stroke, Biofeedback
Effects of Biofeedback in Patients With Acute Cerebral Infarction
The major aim of this study is to investigate the effects of biofeedback assisted abdominal breathing training on improving the psychological and physiological distress in patients with ACI.
- Conditions
- Acute Ischemic Stroke, Biofeedback, Autonomic Dysfunction, Cognitive Function, Psychological Distress
- Trial name
- NCT03516227
- Testing
- heart rate variability biofeedback
- Volunteers
- 40 people
- Sponsor
- National Defense Medical Center, Taiwan
Coronary Artery Disease, Acute Myocardial Ischemia
Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia
The aim of the RIMINI-Trial is to examine the effect of Ranolazine on ischemic myocardium in acute myocardial ischemia. A pilot-trial by Venkatamaran et al.
- Trial name
- RIMINI-Pilot (NCT01797484)
- Testing
- Ranolazine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Acute Ischemic Stroke
Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy
The aim of this study is to find out if DS-1040b is safe and tolerable in acute ischemic stroke patients with thrombectomy. Four groups will receive different doses of DS-1040b by intravenous infusion for 6 hours.
- Trial name
- NCT03198715
- Testing
- DS1040b
- Where
- 20 sites in Japan
- Volunteers
- 42 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Acute Coronary Syndrome
Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)
The purpose of this study is to evaluate the safety of rivaroxaban in patients with recent acute coronary syndrome (ACS) and to assess the ability of rivaroxaban to reduce the occurrence of death, myocardial infarction (heart…
- Trial name
- NCT00402597
- Testing
- Rivaroxaban
- Volunteers
- 3,490 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Ischemic Stroke
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)
- Trial name
- BRIGHT (NCT05403866)
- Testing
- LT3001 Drug Product
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Acute Ischemic Stroke
Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System
Study Objective is to establish the feasibility and safety of the NOVIS Transcarotid Neuroprotection System when used for the transcarotid intervention of patients that have a failed transfemoral endovascular therapy in the case…
- Trial name
- NITE1 (NCT04881162)
- Testing
- NOVIS Transcarotid Neuroprotection System (NPS)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Silk Road Medical
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary
Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions
The central hypothesis for this work is that platelet - leukocyte interactions play a critical role in the pathogenesis of acute ischemic events.
- Conditions
- Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
- Trial name
- NCT01241903
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Susan Smyth
Intracerebral Hemorrhage, Acute Ischemic Stroke
Biologic Mechanisms of Early Exercise After Intracerebral Hemorrhage
This study aims to determine whether in-bed cycle ergometry, early in the hospital course after a brain hemorrhage could balance damaging and reparative inflammation in the brain.
- Trial name
- BEACH (NCT04027049)
- Testing
- Supine cycle ergometry of the lower extremities
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Acute Coronary Syndrome
Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome
This is an open-label phase 2 study recruiting low, moderate, and high likelihood ACS patients from approximately 60 centers. Patients will be imaged with iodofiltic acid I 123 for the detection of myocardial ischemia.
- Trial name
- Zeus-ACS (NCT00514501)
- Testing
- Iodofiltic acid I 123
- Where
- 38 sites in United States, Canada
- Volunteers
- 510 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Acute Myocardial Infarction, STEMI
A Study of Acute Myocardial Infarction Using FDY-5301
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of three dose levels of FDY-5301 compared to placebo in STEMI patients undergoing PCI.
- Trial name
- NCT03470441
- Testing
- FDY-5301
- Where
- 23 sites in United States, Hungary and 2 more
- Volunteers
- 120 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Stroke, Acute
A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours.
- Trial name
- TEMPO-2 (NCT02398656)
- Testing
- Tenecteplase, Antiplatelet treatment
- Where
- 61 sites in Australia, Austria and 8 more
- Volunteers
- 1,274 people
- Sponsor
- University of Calgary
Stroke, Acute
The Role of Hyperoxia in Acute Ischemic Stroke
This study is being conducted to evaluate the potential therapeutic role of hyperoxia when applied in the immediate ischemic period following a stroke in the controlled Emergency Department setting.
- Trial name
- NCT03904017
- Testing
- Oxygen
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Acute Myocardial Infarction
ClearWay Rx Readmission Registry
The purpose of this registry is to determine if delivery of weight adjusted, in a large dose with either Abcixmab or Eptifibitide through the ClearWay™ RX, in patients admitted for primary coronary intervention lowers readmission…
- Trial name
- ClearWay (NCT01673893)
- Testing
- ClearWay™ Rx catheter
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Cardiovascular Institute of the South Clinical Research Corporation
Stroke, Hyperglycemia
Glucose Regulation in Acute Stroke Patients (GRASP) Study
The purpose of this study is to assess the feasibility, safety and preliminary efficacy of the use of insulin infusions as treatment for hyperglycemic acute ischemic stroke patients.
- Trial name
- NCT00282867
- Testing
- IV glucose insulin and potassium, GIK, standard care
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of Virginia
Anterior Wall Acute Myocardial Infarction
Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack
The purpose of this study is to evaluate the feasibility of the delivery of SuperSaturated Oxygen (SSO2) Therapy for 60 minutes selectively into the left main coronary artery (LMCA).
- Trial name
- NCT01630707
- Testing
- SuperSaturated Oxygen (SS02) Therapy
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- TherOx
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Coronary Syndrome, Myocardial Infarction
OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.
The goal of this clinical trial is to compare implementation of a Decision Support System (DSS) - aligned to the 2019 ESC/EAS Guidelines - in addition to routine clinical care versus routine clinical care without availability of…
- Trial name
- ZODIAC (NCT05844566)
- Testing
- Decision Support System (DSS)
- Where
- 42 sites in Italy, Spain and 1 more
- Volunteers
- 1,139 people
- Sponsor
- Imperial College London
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim
Acute Coronary Syndrome, TIA
Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study)
The overall purpose of this project is to determine the feasibility of conducting a randomized clinical trial that compares written exposure therapy with usual care among patients at risk for cardiovascular event-induced PTSD.
- Conditions
- Acute Coronary Syndrome, TIA, Stroke, Cardiac Arrest
- Trial name
- NCT03605693
- Testing
- Written Exposure Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Acute Ischemic Stroke
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
The primary objective of the study is to assess the clinical effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of functional independence and activities of daily living.
- Trial name
- ACTION2 (NCT02730455)
- Testing
- natalizumab
- Where
- 53 sites in United States, Germany and 2 more
- Volunteers
- 277 people
- Sponsor
- Biogen